2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Brad S. Kahl, MD, discusses the current treatment landscape in relapsed/refractory indolent non-Hodgkin lymphoma.
Brad S. Kahl, MD, a medical oncologist at Siteman Cancer Center and a professor of medicine in the Division of Oncology at Washington University School of Medicine in St. Louis, discusses the current treatment landscape in relapsed/refractory indolent non-Hodgkin lymphoma (iNHL).
The management of patients with relapsed/refractory iNHL can be challenging as many factors influence the decision-making process, says Kahl.
Patient-specific factors such as age, comorbidities, and goals of treatment should be considered, Kahl explains. Additionally, it is important to note all prior treatments the patient had received and how well they responded to them.
Notably, if a patient derived a substantial response from a frontline therapy with minimal toxicity, it may be reasonable to offer that therapy again. However, as there are many therapeutic options in this space, this does not happen often, Kahl concludes.